February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: It’s About Time

International Conference on Alzheimer’s and Parkinson’s Disease 2018

Introduction to Our Patient: Patient History and Presentation for a Patient with Early Stages of Alzheimer’s Disease
Neuropsychological Tools: Assessment of the Appropriate Cognitive Domains in the Diagnosis of the Early Alzheimer’s Disease

Panel chair José Luis Molinuevo, MD, PhD, introduces a patient case study that follows the journey of a patient in the early stages of Alzheimer’s disease, throughout the symposium, from initial clinical presentation to receiving a diagnosis of MCI due to Alzheimer’s disease.
James Galvin, MD, describes the neurocognitive domains and use of informant measures and clinical assessments to detect early Alzheimer’s disease, discussing the advantages and disadvantages of each assessment. He then discusses the results of the neuropsychological assessment from the patient case and outlines the importance of assessing the appropriate cognitive domains during patient evaluation.

Download Key Learnings

Summary of key learnings from Biogen’s AAT-ADPD 2018 Symposium

Key Learning Objectives for Biogen’s AAT-AD/PD 2018 Symposium:

  • Understand the importance of an early diagnosis of Alzheimer’s disease
  • Gain insights on the use of cognitive assessment tools to achieve an early diagnosis of Alzheimer’s disease
  • Understand how fluid and imaging biomarkers can be used to achieve an accurate and timely diagnosis of Alzheimer’s disease in the early stages
  • Increase understanding of management options for patients diagnosed with Alzheimer’s disease in the early stages

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.